
Part 1: Complexities in Data Collection Blog Post
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara highlights challenges with data volume and complexity.
In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara highlights challenges with data volume and complexity.
Connecting Cancer and Autoimmunity “The dosing regimens in oncology may not directly inform the optimal choices in autoimmune diseases from an efficacy or safety perspective.” The level of immune activation…
Background Monkeys and humans share a strong bond, reflected not only in a shared genetic heritage, but in history and folklore. In Chinese literature from the 16th century, Journey to the…
In this podcast, Dr. Chris Bouton, Senior VP and Head of AI at Certara, highlights how generative AI is being applied to increase the efficiency of drug discovery and development….
The article titled “Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women,” authored by Jia Ning, Amita Pansari,…
Discover the 6 dos and don’ts of creating compliant define.xml files for FDA submission with our free, downloadable Define-XML format guide.
Learn how to easily manage and validate against CDISC data standards our complete guide to CDISC standards management.
RADNOR, PA – October 30, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Dr. Tong Zhu, FCP, to lead its…
Abstract: T cell interaction in the tumor microenvironment is a key component of immuno-oncology therapy. Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) is expressed on immune cells including regulatory…